Resources from the same session
Risk prediction for patients with early HR+, HER2-, node-positive breast cancer: How to best integrate clinicopathologic and genomic tests?
Presenter: Christos Sotiriou
Session: ESMO Colloquium supported by Lilly - Optimising risk prediction, management and compliance for patients with early HR+ HER2- breast cancer: The start of a journey
Resources:
Slides
Webcast
An overview of the adjuvant trials evaluating CDK4/6 inhibitors in early HR+ HER2- breast cancer
Presenter: Fatima Cardoso
Session: ESMO Colloquium supported by Lilly - Optimising risk prediction, management and compliance for patients with early HR+ HER2- breast cancer: The start of a journey
Resources:
Slides
Webcast
A case on localised HR+, HER- breast cancer treated with adjuvant therapy/abemaciclib
Presenter: Valentina Guarneri
Session: ESMO Colloquium supported by Lilly - Optimising risk prediction, management and compliance for patients with early HR+ HER2- breast cancer: The start of a journey
Resources:
Slides
Webcast
Shaping an emerging continuum of care for patients with HR+, HER2- breast cancer: Which patients to select, from localized to recurrent disease
Presenter: Thomas Bachelot
Session: ESMO Colloquium supported by Lilly - Optimising risk prediction, management and compliance for patients with early HR+ HER2- breast cancer: The start of a journey
Resources:
Slides
Webcast
Shaping an emerging continuum of care for patients with HR+, HER2- breast cancer: A case on metastatic breast cancer treated with CDK4/6 inhibitors
Presenter: Thomas Bachelot
Session: ESMO Colloquium supported by Lilly - Optimising risk prediction, management and compliance for patients with early HR+ HER2- breast cancer: The start of a journey
Resources:
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: ESMO Colloquium supported by Lilly - Optimising risk prediction, management and compliance for patients with early HR+ HER2- breast cancer: The start of a journey
Resources:
Webcast
Concluding remarks
Presenter: Thomas Bachelot
Session: ESMO Colloquium supported by Lilly - Optimising risk prediction, management and compliance for patients with early HR+ HER2- breast cancer: The start of a journey
Resources:
Webcast